Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 3/20 | 0.44 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639547 | 0.85 | HRH3 (0.44) | HRH3CA1CA2 | |
| SCHEMBL1640798 | 0.85 | HRH3 (0.45) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL1640533 | 0.84 | CA1 (0.36) | HRH3CA1CA2MAPTTP53 | |
| SCHEMBL1640003 | 0.83 | BMPR1B (0.48) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL1640859 | 0.79 | PDE4A (0.40) | CA1CA2POLBTP53KDM4E | |
| SCHEMBL1640521 | 0.79 | BMPR1B (0.48) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL1640497 | 0.78 | HRH3 (0.40) | HRH3CA1CA2POLBKDM4E | |
| SCHEMBL1640483 | 0.78 | HRH3 (0.59) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL1640871 | 0.78 | HRH3 (0.40) | HRH3CA1CA2HSD11B1TP53 | |
| SCHEMBL1638976 | 0.77 | CA1 (0.58) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | claimed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | BMPR1B 1242/4885BMPR1A 1420/4885ACVRL1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.